SURFACE-MARKERS OF HUMAN LYMPHOKINE-ACTIVATED KILLER-CELLS AND THEIR PRECURSORS - ANALYSIS AT THE POPULATION AND CLONAL LEVEL

被引:21
作者
FERRINI, S
MORETTA, L
PANTALEO, G
MORETTA, A
机构
[1] IST NAZL RIC CANC, PHARMOCOL LAB, V BENEDETTO XV 10, I-16132 GENOA, ITALY
[2] IST NAZL RIC CANC, IMMUNOPATHOL LAB, I-16132 GENOA, ITALY
[3] LUDWIG INST CANC RES, LAUSANNE BRANCH, CH-1066 EPALINGES, SWITZERLAND
关键词
D O I
10.1002/ijc.2910390105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lymphokine-activated killer (LAK) activity was first analyzed on PBL populations fractionated on the basis of the expression of T11 or T3 antigen. LAK cell precursors were found to be present in both T11+ and T11- populations, but only in the T3- cell fraction. The generation of LAK activity in highly purified T3- populations of PBL was not accompanied by expression of T3 antigen during a 5-day culture period. LAK activity was next analyzed at the level of limiting dilution clonal microcultures. T11-T3- and T11+T3+ cells, cloned under optimal culture conditions, gave a frequency of proliferating cells of approximately 1 cell in 1.25 for T11+T3+ and 1 cell in 10 for T11+T3- cells. Clones were screened for their ability to lyse fresh ovarian carcinoma cells and K562 target cells. The majority of LAK clones were derived from the T11+T3- cells; moreover, most of the clones derived from these cells displayed LAK activity. Clones displaying LAK activity lysed a panel of fresh or cultured tumor target cells, but failed to lyse PHA-activated lymphoblasts. Surface marker analysis indicated that all the clones had maintained the original T11/T3 phenotype. Whereas 2 T3+ selected LAK clones expressed the T8+T4- phenotype, only 1 out of 9 T3- clones was T8+T4-, all the others lacking both T4 and T8 antigens.
引用
收藏
页码:18 / 24
页数:7
相关论文
共 25 条
[1]   INDUCTION OF CYTOTOXICITY BY INTERLEUKIN-2 IN T-GAMMA-LYMPHOPROLIFERATIVE DISORDERS [J].
ALLAVENA, P ;
INTRONA, M ;
RAMBALDI, A ;
ZANABONI, F ;
ROSSINI, S ;
VILLA, A ;
BASSAN, R ;
BARBUI, T ;
MANTOVANI, A .
INTERNATIONAL JOURNAL OF CANCER, 1986, 37 (01) :27-33
[2]  
ALLAVENA P, 1984, J IMMUNOL, V132, P2363
[3]   MOLECULAR-CLONING OF HUMAN INTERLEUKIN-2 CARRIER DNA AND ITS EXPRESSION IN ESCHERICHIA-COLI [J].
DEVOS, R ;
PLAETINCK, G ;
CHEROUTRE, H ;
SIMONS, G ;
DEGRAVE, W ;
TAVERNIER, J ;
REMAUT, E ;
FIERS, W .
NUCLEIC ACIDS RESEARCH, 1983, 11 (13) :4307-4323
[4]   LYMPHOKINE-ACTIVATED KILLER CELL PHENOMENON .3. EVIDENCE THAT IL-2 IS SUFFICIENT FOR DIRECT ACTIVATION OF PERIPHERAL-BLOOD LYMPHOCYTES INTO LYMPHOKINE-ACTIVATED KILLER CELLS [J].
GRIMM, EA ;
ROBB, RJ ;
ROTH, JA ;
NECKERS, LM ;
LACHMAN, LB ;
WILSON, DJ ;
ROSENBERG, SA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1983, 158 (04) :1356-1361
[5]   LYMPHOKINE-ACTIVATED KILLER CELL PHENOMENON - LYSIS OF NATURAL KILLER-RESISTANT FRESH SOLID TUMOR-CELLS BY INTERLEUKIN 2-ACTIVATED AUTOLOGOUS HUMAN PERIPHERAL-BLOOD LYMPHOCYTES [J].
GRIMM, EA ;
MAZUMDER, A ;
ZHANG, HZ ;
ROSENBERG, SA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (06) :1823-1841
[6]   LYMPHOKINE-ACTIVATED KILLER CELL PHENOMENON .2. PRECURSOR PHENOTYPE IS SEROLOGICALLY DISTINCT FROM PERIPHERAL LYMPHOCYTES-T, MEMORY CYTO-TOXIC THYMUS-DERIVED LYMPHOCYTES, AND NATURAL-KILLER CELLS [J].
GRIMM, EA ;
RAMSEY, KM ;
MAZUMDER, A ;
WILSON, DJ ;
DJEU, JY ;
ROSENBERG, SA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1983, 157 (03) :884-897
[7]   PHENOTYPIC AND FUNCTIONAL-HETEROGENEITY OF HUMAN CLONED NATURAL-KILLER CELL-LINES [J].
HERCEND, T ;
REINHERZ, EL ;
MEUER, S ;
SCHLOSSMAN, SF ;
RITZ, J .
NATURE, 1983, 301 (5896) :158-160
[8]  
ITOH K, 1985, J IMMUNOL, V134, P802
[9]   HUMAN CYTO-TOXIC T-CELL STRUCTURES ASSOCIATED WITH EXPRESSION OF CYTOLYSIS .1. ANALYSIS AT THE CLONAL CELL LEVEL OF THE CYTOLYSIS-INHIBITING EFFECT OF 7 MONOCLONAL-ANTIBODIES [J].
MALISSEN, B ;
REBAI, N ;
LIABEUF, A ;
MAWAS, C .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1982, 12 (09) :739-747
[10]   NATURAL-KILLER ACTIVITY OF LYMPHOID-CELLS ISOLATED FROM HUMAN ASCITIC OVARIAN-TUMORS [J].
MANTOVANI, A ;
ALLAVENA, P ;
SESSA, C ;
BOLIS, G ;
MANGIONI, C .
INTERNATIONAL JOURNAL OF CANCER, 1980, 25 (05) :573-582